Shaanxi Kanghui Pharm Co Ltd - Asset Resilience Ratio

Latest as of March 2026: 0.01%

Shaanxi Kanghui Pharm Co Ltd (603139) has an Asset Resilience Ratio of 0.01% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 603139 working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥252.20K
≈ $36.90K USD Cash + Short-term Investments

Total Assets

CN¥1.71 Billion
≈ $249.51 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2019–2025)

This chart shows how Shaanxi Kanghui Pharm Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 603139 total asset value.

Liquid Assets Composition Over Time

This chart breaks down Shaanxi Kanghui Pharm Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read 603139 current and long-term liabilities for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥252.20K 0.01%
Total Liquid Assets CN¥252.20K 0.01%

Asset Resilience Insights

  • Limited Liquidity: Shaanxi Kanghui Pharm Co Ltd maintains only 0.01% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Shaanxi Kanghui Pharm Co Ltd Industry Peers by Asset Resilience Ratio

Compare Shaanxi Kanghui Pharm Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
Drug Manufacturers - Specialty & Generic 1.54%
Takeda Pharmaceutical Company Limited
F:TKDA
Drug Manufacturers - Specialty & Generic 0.69%
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
Drug Manufacturers - Specialty & Generic 20.44%
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
Drug Manufacturers - Specialty & Generic 47.16%
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
Drug Manufacturers - Specialty & Generic 6.62%
Piramal Pharma Limited
NSE:PPLPHARMA
Drug Manufacturers - Specialty & Generic 0.73%
Harbin Gloria Pharmaceuticals
SHE:002437
Drug Manufacturers - Specialty & Generic 9.04%
Renhe Pharmacy Co Ltd
SHE:000650
Drug Manufacturers - Specialty & Generic 37.54%

Annual Asset Resilience Ratio for Shaanxi Kanghui Pharm Co Ltd (2019–2025)

The table below shows the annual Asset Resilience Ratio data for Shaanxi Kanghui Pharm Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 0.01% CN¥252.20K
≈ $36.90K
CN¥1.81 Billion
≈ $265.51 Million
-0.01pp
2024-12-31 0.02% CN¥359.18K
≈ $52.56K
CN¥1.89 Billion
≈ $276.25 Million
-0.13pp
2023-12-31 0.15% CN¥3.02 Million
≈ $441.85K
CN¥2.05 Billion
≈ $300.23 Million
-0.10pp
2022-12-31 0.25% CN¥4.50 Million
≈ $658.73K
CN¥1.82 Billion
≈ $266.57 Million
-6.18pp
2021-12-31 6.42% CN¥119.47 Million
≈ $17.48 Million
CN¥1.86 Billion
≈ $272.21 Million
+2.19pp
2020-12-31 4.23% CN¥55.47 Million
≈ $8.12 Million
CN¥1.31 Billion
≈ $191.87 Million
-12.75pp
2019-12-31 16.98% CN¥192.00 Million
≈ $28.10 Million
CN¥1.13 Billion
≈ $165.45 Million
--
pp = percentage points

About Shaanxi Kanghui Pharm Co Ltd

SHG:603139 China Drug Manufacturers - Specialty & Generic
Market Cap
$554.37 Million
CN¥3.79 Billion CNY
Market Cap Rank
#11816 Global
#3388 in China
Share Price
CN¥37.93
Change (1 day)
-3.02%
52-Week Range
CN¥20.27 - CN¥45.21
All Time High
CN¥45.21
About

Shaanxi Kanghui Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical intermediates in China. It is involved in the research, development, production, and sale of traditional Chinese medicine preparations; research and development of prepared slices of Chinese medicinal herbs and pharmaceutical intermediates; and pharmaceutical distribution of biolo… Read more